Informing mechanistic toxicology with computational molecular models.
暂无分享,去创建一个
Yu-Mei Tan | Rogelio Tornero-Velez | Michael R Goldsmith | Shane D Peterson | Daniel T Chang | Thomas R Transue | Curtis C Dary
[1] S. Ekins,et al. Pharmacophore and three-dimensional quantitative structure activity relationship methods for modeling cytochrome p450 active sites. , 2001, Drug metabolism and disposition: the biological fate of chemicals.
[2] S. Wold,et al. The Collinearity Problem in Linear Regression. The Partial Least Squares (PLS) Approach to Generalized Inverses , 1984 .
[3] Ettore Novellino,et al. A Critical Review of Recent CoMFA Applications , 1998 .
[4] Sorel Muresan,et al. ChemGPS-NP: tuned for navigation in biologically relevant chemical space. , 2006, Journal of natural products.
[5] Michael M. Mysinger,et al. Computational models for cytochrome P450: a predictive electronic model for aromatic oxidation and hydrogen atom abstraction. , 2002, Drug metabolism and disposition: the biological fate of chemicals.
[6] S. Peterson. Improved CoMFA Modeling by Optimization of Settings : Toward the Design of Inhibitors of the HCV NS3 Protease , 2007 .
[7] S. Pickett,et al. GRid-INdependent descriptors (GRIND): a novel class of alignment-independent three-dimensional molecular descriptors. , 2000, Journal of medicinal chemistry.
[8] Paul T Anastas,et al. Toward a comprehensive molecular design framework for reduced hazard. , 2010, Chemical reviews.
[9] R. Cramer,et al. Comparative molecular field analysis (CoMFA). 1. Effect of shape on binding of steroids to carrier proteins. , 1988, Journal of the American Chemical Society.
[10] T. Halgren. Merck molecular force field. I. Basis, form, scope, parameterization, and performance of MMFF94 , 1996, J. Comput. Chem..
[11] Peter A. Kollman,et al. AMBER, a package of computer programs for applying molecular mechanics, normal mode analysis, molecular dynamics and free energy calculations to simulate the structural and energetic properties of molecules , 1995 .
[12] W. L. Jorgensen,et al. Development and Testing of the OPLS All-Atom Force Field on Conformational Energetics and Properties of Organic Liquids , 1996 .
[13] Y.Z. Chen,et al. Ligand–protein inverse docking and its potential use in the computer search of protein targets of a small molecule , 2001, Proteins.
[14] R. Campbell,et al. Molecular modeling of the human multidrug resistance protein 1 (MRP1/ABCC1). , 2008, Biochemical and biophysical research communications.
[15] Melissa A. Pasquinelli,et al. Computational Molecular Modeling for Evaluating the Toxicity of Environmental Chemicals: Prioritizing Bioassay Requirements , 2008, Environmental health perspectives.
[16] Norman L. Allinger,et al. Molecular mechanics. The MM3 force field for hydrocarbons. 1 , 1989 .
[17] Y. Cheng,et al. Relationship between the inhibition constant (K1) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reaction. , 1973, Biochemical pharmacology.
[18] K. Maeda,et al. Estimation of the Three-Dimensional Pharmacophore of Ligands for Rat Multidrug-Resistance–Associated Protein 2 Using Ligand-Based Drug Design Techniques , 2005, Pharmaceutical Research.
[19] Gabriele Cruciani,et al. Predicting human serum albumin affinity of interleukin-8 (CXCL8) inhibitors by 3D-QSPR approach. , 2005, Journal of medicinal chemistry.
[20] S. Ekins,et al. Three-dimensional quantitative structure-activity relationships of inhibitors of P-glycoprotein. , 2002, Molecular pharmacology.
[21] D. Dix,et al. The ToxCast program for prioritizing toxicity testing of environmental chemicals. , 2007, Toxicological sciences : an official journal of the Society of Toxicology.
[22] Jennifer L. Perry,et al. Structure of the ochratoxin A binding site within human serum albumin , 2004 .
[23] John J. Irwin,et al. Community benchmarks for virtual screening , 2008, J. Comput. Aided Mol. Des..
[24] David F. V. Lewis,et al. Molecular modeling of human cytochrome P450–substrate interactions , 2002, Drug metabolism reviews.
[25] Yongbo Hu,et al. Comparison of Several Molecular Docking Programs: Pose Prediction and Virtual Screening Accuracy , 2009, J. Chem. Inf. Model..
[26] H A Scheraga,et al. A comparison of the CHARMM, AMBER and ECEPP potentials for peptides. I. Conformational predictions for the tandemly repeated peptide (Asn-Ala-Asn-Pro)9. , 1989, Journal of biomolecular structure & dynamics.
[27] Jin-Young Park,et al. Construction and assessment of models of CYP2E1: predictions of metabolism from docking, molecular dynamics, and density functional theoretical calculations. , 2003, Journal of medicinal chemistry.
[28] Ulf Norinder,et al. 3D‐QSAR investigation of the tripos benchmark steroids and some protein‐tyrosine kinase inhibitors of styrene type using the TDQ approach , 1996 .
[29] F. Lombardo,et al. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings , 1997 .
[30] Artem Cherkasov,et al. Progressive docking: a hybrid QSAR/docking approach for accelerating in silico high throughput screening. , 2006, Journal of medicinal chemistry.
[31] M. Karplus,et al. CHARMM: A program for macromolecular energy, minimization, and dynamics calculations , 1983 .
[32] Olivier Sperandio,et al. Free resources to assist structure-based virtual ligand screening experiments. , 2007, Current protein & peptide science.
[33] Thierry Kogej,et al. ChemGPS-NPWeb: chemical space navigation online , 2009, J. Comput. Aided Mol. Des..
[34] Hugo Kubinyi,et al. From Narcosis to Hyperspace: The History of QSAR , 2002 .
[35] Roland L Dunbrack,et al. Outcome of a workshop on applications of protein models in biomedical research. , 2009, Structure.
[36] C. Wermuth,et al. Glossary of terms used in medicinal chemistry (IUPAC Recommendations 1998) , 1998 .
[37] Michael-Rock Goldsmith,et al. Molecular modeling for screening environmental chemicals for estrogenicity: use of the toxicant-target approach. , 2009, Chemical research in toxicology.
[38] Tudor I. Oprea,et al. Chemical database preparation for compound acquisition or virtual screening. , 2006, Methods in molecular biology.
[39] Ulf Norinder,et al. Recent Progress in CoMFA Methodology and Related Techniques , 1998 .
[40] Michael M. Mysinger,et al. Automated Docking Screens: A Feasibility Study , 2009, Journal of medicinal chemistry.
[41] A. Leo,et al. Partition coefficients and their uses , 1971 .
[42] T. Cheatham,et al. Molecular dynamics simulation of nucleic acids: Successes, limitations, and promise * , 2000, Biopolymers.
[43] I. Rusyn,et al. Computational Toxicology: Realizing the Promise of the Toxicity Testing in the 21st Century , 2010, Environmental health perspectives.
[44] G. W. Price,et al. Differences in the central nervous system distribution and pharmacology of the mouse 5-hydroxytryptamine-6 receptor compared with rat and human receptors investigated by radioligand binding, site-directed mutagenesis, and molecular modeling. , 2003, Molecular pharmacology.
[45] M. Hartmann. Molecular mechanics. Von ULRICH BURKERT und NORMAN L. ALLINGER. ACS Monograph 177. Washington: American Chemical Society 1982. 430 S., US $ 77.95 , 1984 .
[46] Jianpeng Ma,et al. CHARMM: The biomolecular simulation program , 2009, J. Comput. Chem..
[47] F. Ban,et al. In silico identification of anthropogenic chemicals as ligands of zebrafish sex hormone binding globulin. , 2009, Toxicology and applied pharmacology.
[48] Lynda B. M. Ellis,et al. The University of Minnesota Biocatalysis/Biodegradation Database: post-genomic data mining , 2003, Nucleic Acids Res..
[49] G. Klebe,et al. Molecular similarity indices in a comparative analysis (CoMSIA) of drug molecules to correlate and predict their biological activity. , 1994, Journal of medicinal chemistry.
[50] Holger Gohlke,et al. The Amber biomolecular simulation programs , 2005, J. Comput. Chem..
[51] J. Ponder,et al. Force fields for protein simulations. , 2003, Advances in protein chemistry.
[52] Y. Kurogi,et al. Pharmacophore modeling and three-dimensional database searching for drug design using catalyst. , 2001, Current medicinal chemistry.
[53] H. Scheraga,et al. A comparison of the CHARMM, AMBER and ECEPP potentials for peptides. II. Phi-psi maps for N-acetyl alanine N'-methyl amide: comparisons, contrasts and simple experimental tests. , 1989, Journal of biomolecular structure & dynamics.
[54] Lester A. Mitscher,et al. Glossary of terms used in medicinal chemistry , 1998 .
[55] W. L. Jorgensen,et al. The OPLS [optimized potentials for liquid simulations] potential functions for proteins, energy minimizations for crystals of cyclic peptides and crambin. , 1988, Journal of the American Chemical Society.
[56] Sean Ekins,et al. A pharmacophore for human pregnane X receptor ligands. , 2002, Drug metabolism and disposition: the biological fate of chemicals.
[57] K. Gundertofte,et al. A comparison of conformational energies calculated by several molecular mechanics methods , 1996 .